4′ -epi-doxorubicin in advanced lung can
✍
Giuseppe Giaccone; Michela Donadio; Gianmaria Bonardi; Valter Iberti; Alessandro
📂
Article
📅
1990
🏛
Springer US
🌐
English
⚖ 245 KB
Fifty evaluable patients with advanced lung cancer (28 small cell and 22 non-small cell carcinomas), mainly pretreated by chemotherapy, received 4'-epi-doxorubicin 90 mg/m 2 every 3 weeks. Two partial responses were obtained in small cell lung cancer patients, which lasted 153 and 168 days. Leukopen